Literature DB >> 6491948

Factors affecting quinidine protein binding in humans.

D J Edwards, J E Axelson, R L Slaughter, A T Elvin, D Lalka.   

Abstract

The free (unbound) concentration of drug in plasma is often an important determinant of pharmacological and toxicological effects. Unfortunately, studies examining the factors influencing the free fraction of quinidine in plasma have yielded inconsistent results. It is probable that differences in the type of blood collection tubes utilized and the analytical procedure employed biased some of these estimates of quinidine binding. The present study was executed in a manner free of factors now known to introduce artifacts into estimates of the free fraction of quinidine. In healthy volunteers, the free fraction of quinidine (1.0 microgram/mL) was 0.129 +/- 0.019 (mean +/- SD) and was constant throughout the therapeutic range. A high-affinity, low-capacity binding site (K = 1.17 X 10(5) M-1; nP = 3.49 X 10(-5) M) and a low-affinity, high-capacity binding site (K = 1.33 X 10(3) M-1; nP = 3.14 X 10(-3) M) were identified. The characteristics of quinidine binding in a 4.5-g/dL solution of human serum albumin (K = 3.05 X 10(3) M-1; nP = 1.36 X 10(-3) M) suggested that the low-affinity, high-capacity binding site was on this quinidine free fraction increased from 0.114 to 0.231. A lidocaine concentration of 250 micrograms/mL caused a similar increase. Patients suffering traumatic injury had a significant increase in alpha 1-acid glycoprotein concentration (197 mg/dL) and a decreased quinidine free fraction (0.075 +/- 0.019). Patients with hyperlipidemia had free fractions similar to those observed in healthy individuals (0.118 +/- 0.019).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491948     DOI: 10.1002/jps.2600730919

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Protein binding of cocaine in human serum.

Authors:  D J Edwards; S K Bowles
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

4.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

Authors:  Hayley S Brown; Aleksandra Galetin; David Hallifax; J Brian Houston
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  Differences in the binding of quinine and quinidine to plasma proteins.

Authors:  G W Mihaly; M S Ching; M B Klejn; J Paull; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.